Alpha Tau Medical (NASDAQ:DRTS) Given “Buy” Rating at HC Wainwright

Alpha Tau Medical (NASDAQ:DRTS)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They presently have a $16.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 22.74% from the stock’s current price.

Several other brokerages also recently weighed in on DRTS. Barclays raised their price target on shares of Alpha Tau Medical from $17.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, September 3rd. Zacks Research downgraded Alpha Tau Medical from a “hold” rating to a “strong sell” rating in a research note on Tuesday, September 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Alpha Tau Medical in a report on Thursday. Finally, Benchmark restated a “buy” rating on shares of Alpha Tau Medical in a research note on Thursday, July 23rd. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $15.40.

Alpha Tau Medical Trading Up 3.3%

Alpha Tau Medical stock traded up $0.42 during trading hours on Tuesday, reaching $13.04. The company had a trading volume of 700,824 shares, compared to its average volume of 584,112. The company has a debt-to-equity ratio of 0.15, a current ratio of 11.09 and a quick ratio of 7.79. Alpha Tau Medical has a 12-month low of $3.43 and a 12-month high of $15.79. The firm has a market cap of $1.18 billion, a price-to-earnings ratio of -12.54 and a beta of 1.22. The company has a 50-day moving average price of $14.47 and a 200 day moving average price of $11.73.

Alpha Tau Medical (NASDAQ:DRTS) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.36). Equities analysts forecast that Alpha Tau Medical will post -1.05 earnings per share for the current year.

Insider Buying and Selling at Alpha Tau Medical

In related news, CFO Raphi Levy sold 17,730 shares of the stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $14.00, for a total transaction of $248,220.00. Following the transaction, the chief financial officer owned 90,180 shares in the company, valued at $1,262,520. This represents a 16.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 39.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Alpha Tau Medical

A number of hedge funds have recently added to or reduced their stakes in the stock. Everhart Financial Group Inc. purchased a new position in shares of Alpha Tau Medical in the 2nd quarter worth $126,000. Principal Financial Group Inc. purchased a new stake in Alpha Tau Medical during the first quarter valued at $132,000. Finally, Renaissance Technologies LLC purchased a new stake in Alpha Tau Medical during the first quarter valued at $286,000. 2.65% of the stock is currently owned by hedge funds and other institutional investors.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is an Israel-based medical technology company focused on developing localized radiation treatments for solid tumors. Its lead technology, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), is designed to deliver high-energy alpha radiation directly within a tumor while limiting exposure to surrounding healthy tissue.

Alpha DaRT uses implanted radium-224 sources that generate short-lived alpha-emitting atoms. These atoms diffuse through the treated tumor and can damage cancer cells over a localized area.